Replies to post #2510 on Spectrum Pharmaceutecals Inc (SPPI)

[Tartiaboy]

Nice summary: the dose reduction schedule management caught my attention.

Here is the summary of what I understood. There are a range of exon20 insertion mutation, some of these are highly responsive and some are a bit tougher. From Heymach team, SPPI knows which specific exon20 mutations are tougher. The dose reductions go from 16 to 14 to 12, and only with consent down to 10. The inference is that the trial PIs will try hard to maximize the dosing for the hard to treat mutations.

You have a difficult to treat mutation and are having some problems with dosing toxicity. The PI says to you, we really need to keep this dose as high as possible to maximize the efficacy. Can you handle the 12 mg?